The therapeutic effect of Tecar on patients with plantar fasciitis

Not Applicable

• Conditions: Plantar fasciitis.; Plantar fascial fibromatosis; M72.2

• Registration Number: IRCT20231105059968N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diagnosis of plantar fasciitis (worsening of the pain in the inner part of the heel in the morning after waking up and also after a lot of activity during the day and the presence of local tenderness in the lower inner part of the calcaneus) by a physical medicine and rehabilitation specialist with a physical examination
Heel pain for at least 4 weeks
Age between 18 and 68 years
Presence of VAS greater than 3
Informed written consent to participate in the study

Exclusion Criteria

History of inflammatory joint disease
Achilles tendon or nerve damage
History of heel surgery or injection in the last 6 months
History of injury to the affected heel
The presence of diseases mimicking the symptoms of plantar fasciitis
Contraindications of the Tecar device (pregnancy, pacemaker, insulin pump, growth plate, cancer, open wound and skin lesions, skin sensitivity, insensitivity to heat)
Patients with intense physical activity or sports who are unable to reduce their activity level

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain. Timepoint: The severity of symptoms and performance of patients before the treatment will be measured again immediately after the end of the treatment and 2 months after the end of the treatment. Method of measurement: Pain level of patients by Visual Analogue Scale questionnaire - intensity of symptoms and performance of patients by RM(The modified Roles and Maudsley) questionnaire.